|Bid||5.91 x 100|
|Ask||10.64 x 500|
|Day's Range||5.84 - 6.07|
|52 Week Range||5.81 - 27.02|
|PE Ratio (TTM)||-3.31|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||10.50|
IRVINE, CA / ACCESSWIRE / September 21, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Depomed, Inc. ("Depomed" or the "Company") ...
NEW YORK , Sept. 21, 2017 /PRNewswire/ -- Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, reminds investors that October 17, 2017 ...
Categories: Yahoo FinanceGet free summary analysis Depomed, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Depomed, Inc. – BioDelivery Sciences International, Inc., Ironwood Pharmaceuticals, Inc. Class A, Mallinckrodt Plc, Insys Therapeutics, Inc., Merck & Co., Inc., Cara Therapeutics Inc and Pfizer Inc. (BDSI-US, IRWD-US, ... Read more (Read more...)